Clinical and Molecular Predictors of Anti-cytokine Therapy Response in Inflammatory Bowel Disease.
Project no. 20268 · Status: Kapanmış (Yayın bekleniyor) · 2019
Summary
Objective: Inflammatory bowel diseases (IBD) are chronic, autoimmune diseases. Crohn's disease (CH) and ulcerative colitis (UC) are subtypes of IBD. Although anti-cytokine treatments are the current treatment options in IBD, it is not known which factors are determinant in the response to anti-TNF treatment. The aim of this study is to investigate the factors associated with anti-cytokine treatment response in the light of clinical and molecular data in IBD. Materials and Methods: Ten patients who started anti-cytokine therapy were included in the study. Blood and stool samples were taken from the patients at 4 and 72 hours and at 2., 6., and 14. weeks after treatment. Their disease activity and response to anti TNF treatment were evaluated with CDAI and Mayo scores. Results: The average age of the patients included in the study was 38.7 ± 18.2 years, 4 (40%) of them were women. The mean disease duration was 6,3 years, and the follow-up period was 1.8 years. When the group responding to anti-cytokine treatment (n = 8) and the group not (n = 2) were compared, a statistically significant difference was found between the two groups in terms of gender, duration of disease, and disease subtype, respectively (p <0.001), (p = 0.027), (p = 0.018). Discussion and conclusion: According to the results of our study, it was thought that women with a short duration of illness and patients with a diagnosis of UC respond better to anti-TNF treatment.